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Abstract 
The tumor suppressor p53 and its negative regulator MDM2 play crucial roles in a variety of 
cellular functions such as the control of the cell cycle, senescence, genome stability and apoptosis, 
and are frequently deregulated in carcinogenesis. Previous studies have highlighted the 
contribution of the common functional polymorphisms p53 p.Arg72Pro and MDM2 309SNP to the 
risk of both common cancers and Li-Fraumeni syndrome. Their possible role in retinoblastoma has 
recently been addressed by Castera et al, who however only studied the MDM2 309SNP. Here, for 
the first time, we analyzed both SNPs in a case-control study of 111 Italian hereditary 
retinoblastoma patients. We found a significant association of the p53 Pro/Pro genotype with the 
disease (OR=3.58, p= 0.002). The MDM2 309SNP showed a weak negative association of allele G 
that deserves further investigation. These findings further support the hypothesis that genetic 
variability of the p53 pathway contributes to the individual susceptibility to retinoblastoma, as 







Retinoblastoma (RB, OMIM#180200), the most common primary intraocular malignancy in 
children, affecting 1: 14 000 to 1:22 000 live births, is caused by biallelic inactivation of RB11. In 
about 40% of patients a germ-line mutation inactivates one allele and a somatic one the second 
allele (hereditary RB), while in non-hereditary RB both alleles are inactivated somatically. 
Although most children with hereditary RB show multiple bilateral tumors, a significant proportion 
of carriers remain unaffected or only develop unilateral tumors, or benign retinomas2. Penetrance 
and expressivity of hereditary RB may depend on the type of inherited mutation, and can vary even 
within families and among patients with identical mutations3-5. This indicates a role of modifiers 
that may affect genome stability to favor the occurrence of somatic mutations, and/or the apoptotic 
pathway to induce loss or maintenance of the mutated retinoblasts.  
 The p53 pathway, the master control system of these processes, is controlled by a feedback 
autoregulatory loop in which p53 transcriptionally activates MDM2, that in turn acts as a negative 
regulator by promoting the proteolytic degradation of p53. Interestingly, this circuit can also target 
pRB to degradation and in physiological condition controls the cell cycle and apoptosis of the 
retinal cone precursors, from which the RB cell lineage originates6. In RB p53 is not usually 
mutated nor is MDM2 amplified. Rather, the expression of MDM2 is highly induced and represses 
p536, thus leaving ample space for constitutional polymorphism of p53 and/or MDM2 to affect the 
fate of the RB lineage. 
The 72Pro allele of p53 SNP (p.Arg72Pro, rs1042522:G>C) features a reduced proapototic 
activity compared with the 72Arg allele, and together with its more efficient induction of the 
MDM2 gene and other p53 targets eventually results in attenuation of the p53 pathway7. 
 The G allele of MDM2 309SNP (c.14+309T>G, rs2279744:T>G), adjacent to p53-
responsive elements of the inducible intronic P2 promoter, activates MDM2 transcription8 and 
results in overdegradation of p539. Several studies have highlighted the risk-modifying effect of 
these polymorphisms in common cancers and the rare Li-Fraumeni syndrome caused by germinal 
TP53 mutations10,11,12. The possible role of the MDM2 309SNP in RB has only recently been 
addressed through a family-based approach13.  
For the first time we here investigated both SNPs. We took advantage of a sample of 111 
RB patients with known germinal RB1 mutation (50% M, 93 bilateral cases, median age at 
diagnosis 22.75 months (IQR 10.29-37.79)) from the Italian DataBase of Retinoblastoma, referred 
to the Medical Genetics Unit of Siena since 2003 for germline RB1 mutations testing. Written 
consent was obtained from all subjects or their legal tutors. Controls were 307 unrelated Italian 
individuals. 
The two SNPs were genotyped on blood DNA using Pyrosequencing®, according to 
standard protocols. PCR and sequencing primers were designed using the PSQ Assay Design 
Software version 1.0.6 (Biotage AB, Uppsala, Sweden, now Qiagen) and are available on request. 
Pyrograms were analyzed using the PSQ96MA 2.0.2 software. The association of each SNP and of 
the combined genotypes were analyzed in a case-control design using logistic regression with 
Firth’s bias reduction procedure to assess their effect on the disease risk. 
Allele frequencies of the p53 SNP were Arg 0.68 and Pro 0.32 among RB patients vs 0.78 
and 0.22 in controls, those of the MDM2 309SNP T 0.66 and G 0.34 vs 0.59 and 0.41. The 
genotype frequencies of patients and controls were in Hardy-Weinberg equilibrium for both 
polymorphisms. The Pro/Pro genotype was significantly disease-associated compared with the 
Arg/Arg (Table 1a); the heterozygous Arg/Pro was also increased but not significantly. The MDM2 
309SNP showed a weak negative association of the G allele; the GT genotype was significant 
within the Arg/Arg subgroup (Table 1b). 
For the first time we show that the association of the Pro/Pro genotype, well known in other 
cancers, also holds true in hereditary RB. p53 has a central role as tumor suppressor but is not 
mutated in RB14-16. It has been suggested that RB precursor are intrinsically apoptosis-resistant 
cells 17. However, there is evidence in mice and humans that the p53 pathway plays a central role in 
regulating the progression of RB cells from quiescent retinoma to overt disease2,18. Two features of 
the p53 72Pro allele can be hypothesized to contribute to this outcome i.e. its increased 
transcriptional activity on target genes and the weaker interaction with the MDM2 protein, the first 
by enhancing MDM2 hyperexpression, and the second by downregulating the mitochondrial 
control of the apoptotic pathway7. 
On the other hand, our finding of a weak negative association of the MDM2 G allele is in contrast 
with reports of its preferential transmission to RB patients13, modifier role in Li-Fraumeni 
syndrome9,19 and association with common cancers20. Nevertheless our findings seem plausible, 
considering that the association only holds in p53-mutated cancers20. If confirmed in other 
independent studies, the pattern we report here of positive association of p53 Pro/Pro and negative 
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